Cgrp May Play A Causative Role in Migraine

@article{Lassen2002CgrpMP,
  title={Cgrp May Play A Causative Role in Migraine},
  author={L. H. Lassen and PA Haderslev and V. B. Jacobsen and H. K. Iversen and Bj{\o}rn Sperling and Jes Olesen},
  journal={Cephalalgia},
  year={2002},
  volume={22},
  pages={54 - 61}
}
Calcitonin gene-related peptide (CGRP) has been detected in increased amounts in external jugular venous blood during migraine attacks. However, it is unknown whether this is secondary to migraine or whether CGRP may cause headache. In a double-blind crossover study, the effect of human αCGRP (2 μg/min) or placebo infused intravenously for 20 min was studied in 12 patients suffering from migraine without aura. Headache intensity was scored on a scale from 0 to 10. Two patients were excluded due… 

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

TLDR
Data indicate similar neurobiological pathways responsible for triggering migraine headache in MA and MO patients, and suggest differences between MA/MO and FHM.

Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache

TLDR
The current state of knowledge on the role of CGRP in CH pathology, and as a target for future treatments is summarized.

Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine

TLDR
It seems that peripheral CGRP levels are a good biomarker of acute migraine and somewhat specific and sensitive interictally in chronic migraine.

The Headache-Inducing Effect of Cilostazol in Human Volunteers

TLDR
Increased levels of cAMP may play a role in headache and migraine pathogenesis, and the headache after cilostazol was equal to or more severe than headache induced by glyceryl trinitrate in previous experiments.

Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura

TLDR
The migraine-like attacks during, and immediately after, the PGE2 infusion contrast with those found in previous provocation studies, in which the other pharmacological compounds triggered the delayed migraine- like attacks several hours after the infusion.

No increase of calcitonin gene–related peptide in jugular blood during migraine

TLDR
Previous findings of increased CGRP level in external jugular or cubital fossa venous blood could not be confirmed and this finding strongly suggests that C GRP is not increased in jugular venousBlood during migraine without aura.

Calcitonin gene related peptide (CGRP)–provoked migraine-like attacks

  • F. CutrerP. Mathew
  • Psychology, Medicine
    Cephalalgia : an international journal of headache
  • 2010
TLDR
The series of CGRP infusion experiments reported by Dr Hansen and colleagues postulate that the mechanism of headache induction in migraine with typical aura and migraine without aura are likely to be similar, but that the mechanisms in familial hemiplegic migraine may be distinct.

PACAP38 induces migraine-like attacks in patients with migraine without aura.

TLDR
Pituitary adenylate cyclase activating peptide-38 infusion caused headache and vasodilatation in both healthy subjects and migraine patients and caused delayed migraine-like attacks in migraine sufferers.

Calcitonin gene–related peptide does not cause the familial hemiplegic migraine phenotype

TLDR
Familial hemiplegic migraine patients do not show hypersensitivity of the calcitonin gene–related peptide (CGRP)–cyclic adenosine 3′,5′-monophosphate pathway, as characteristically seen in migraine patients without aura, which indicates that the pathophysiologic pathways underlying migraine headache in FHM may be different from the common types of migraine.
...

References

SHOWING 1-10 OF 29 REFERENCES

A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks

TLDR
It is demonstrated that activation of the nitric oxide cGMP pathway may cause typical migraine attacks.

Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies.

TLDR
Patients with episodic cluster headache fulfilling the criteria of the International Headache Society were examined during an acute spontaneous attack of headache to determine the local cranial release of neuropeptides to demonstrate in vivo human evidence for activation of the trigeminovascular system and the cranial parasympathetic nervous system.

Histamine induces migraine via the H1‐receptor. Support for the NO hypothesis of migraine

TLDR
It is suggested that a migraine attack can be caused by NO formation in the endothelium of cerebral arteries in patients given histamine-H1-receptor antagonist.

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

TLDR
A substantial elevation of the calcitonin gene‐related peptide level in the external jugular but not the cubital fossa blood was seen in both classic and common migraine, and may have importance in the pathophysiology of migraine.

Haemodynamic effects of intravenous human calcitonin-gene-related peptide in man.

TLDR
It is concluded that systemic administration of hCGRP produces tachycardia and stimulation of the sympathetic nervous system in the absence of any change in blood pressure.

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

TLDR
In an in vivo model, BIBN4096BS in doses between 1 and 30 μg kg−1 (i.v.) inhibited the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys, and it was concluded that BIBn40 96BS is a potent and selective CGRp antagonist.

The Nitric Oxide Hypothesis of Migraine and Other Vascular Headaches

TLDR
The importance of NO as a potential initiator of the migraine attack indicates new directions for the pharmacological treatment of migraine and other vascular headaches.

The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats

TLDR
These data characterize some aspects of the cerebrovascular physiology of the trigeminovascular system and demonstrate important interactions between this system and the effective antimigraine agents sumatriptan and dihydroergotamine and that such interactions can be represented in animal models.